Results 101 to 110 of about 58,749 (205)

Polymyxin-Associated Neurotoxicity: A Case of Guillain-Barré Syndrome Temporally Linked to Colistin Methanesulfonate and Respiratory Paralysis with Polymyxin B. [PDF]

Infect Drug Resist
Huang J, He J, Li L, Li W, Zhang K, Ma L, Bian X.   +6 more
europepmc   +1 more source

Integration of Polymyxin-B Hemoadsorption Device into a CRRT Circuit for Endotoxic Septic Shock in a Child: A Case Report. [PDF]

Pediatr Rep
Ceschia G, Longo G, Miguel JMIS, Daverio M, Vidal E.   +4 more
europepmc   +1 more source

In Vitro and In Silico Evaluation of Polymyxin B Aerosol Delivery in Adult Mechanical Ventilation. [PDF]

Pharmaceutics
Zhang S, Wang G, Liu J, Zhang X, Pei Q.
europepmc   +1 more source

Evaluation of Polymyxin B as a Novel Vaccine Adjuvant and Its Immunological Comparison with FDA-Approved Adjuvants. [PDF]

Vaccines (Basel)
Gulani M, Harsoda Y, Arte T, D'Souza MJ, Bagwe P, Adediran E, D'Souza N, Pasupuleti D.   +7 more
europepmc   +1 more source

<i>Sapindus mukorossi</i> as a Bioenhancer for the Biocidal Action of Polymyxin B. [PDF]

ACS Omega
Makiej A, Smułek W, Dubrowska K, Augustyniak A, Bernat P, Kaczorek E.   +5 more
europepmc   +1 more source

Polymyxin B lethality requires energy-dependent outer membrane disruption. [PDF]

Nat Microbiol
Borrelli C, Douglas EJA, Riley SMA, Lemonidi AE, Larrouy-Maumus G, Lu WJ, Bonev BB, Edwards AM, Hoogenboom BW.   +8 more
europepmc   +1 more source

Subconjunctival Injection of Polymyxin B [PDF]

British Journal of Ophthalmology, 1953
openaire   +2 more sources

Polymyxin B Induced Acute Diaphragmatic Paralysis: A Case Report Based on Therapeutic Drug Monitoring. [PDF]

Pharmacol Res Perspect
Zhang Y, Tang X, Li Y, Su X, Zhong X, Huang Z.   +5 more
europepmc   +1 more source

Combination Therapy of Cefiderocol and Polymyxin B Against Pseudomonas aeruginosa Keratitis Isolates In Vitro. [PDF]

Transl Vis Sci Technol
Romanowski EG, Young EK, Mumper SM, Yates KA, Wozniak RAF, Zegans ME, Shanks RMQ.   +6 more
europepmc   +1 more source

Introducing CLipPA lipid chemodiversity to enzymatically truncated polymyxin B: a soft drug strategy to combat Gram-negative pathogens. [PDF]

RSC Med Chem
Na TU, Hermant YO, Siow A, Owen JG, Chan STS, Painter GF, Hanna CC, Daysh Z, Goggin BL, Allison JR, Sander V, Davidson AJ, Campbell G, Ferguson SA, Cook GM, Harris PWR, Brimble MA, Cameron AJ.   +17 more
europepmc   +1 more source